. Author manuscript; available in PMC: 2022 Jun 10.

Published in final edited form as: NEJM Evid. 2022 Apr 11;1(5):EVIDoa2100056. doi: 10.1056/EVIDoa2100056

Table 3:

Participants experiencing adverse events (ITT)

	Randomized Arm
	Nonavalent HPV	Bivalent HPV	Meningococcal	All

Enrolled, n	758	760	757	2275
Any SAE, n(%)	34 (4.5%)	39 (5.1%)	39 (5.2%)	112 (4.9%)
Any pregnancy related, n (%)	24 (3.2%)	19 (2.5%)	14 (1.8%)	57 (2.5%)
Any infection/inflammation, n (%)	9 (1.2%)	16 (2.1%)	21 (2.8%)	46 (2.0%)
Any injury, n (%)	0 (0.0%)	3 (0.4%)	4 (0.5%)	7 (0.3%)
Any mental health, n (%)	2 (0.3%)	1 (0.1%)	2 (0.3%)	5 (0.2%)

NOTE: Participants may have more than one event across, but not within, event type categories. SAE: Serious adverse event